跳至主要内容
临床试验/NCT06228638
NCT06228638招募中不适用

CognivAiD Real-World Evidence Clinical Registry

Moleac Pte Ltd.1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2023年12月12日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
100
试验地点
1
主要终点
Safety reporting

研究概览

简要总结

This is an observational, prospective cohort of patients who were prescribed or have taken CognivAiD as prescribed by the attending physician. The safety and efficacy of CognivAiD have been established in clinical studies. The registry will assess the safe use and effectiveness of CognivAiD in a real-world setting. The registry is designed as a product registry in clinical practice. The design also takes into account the different scenarios of product use in the real world (e.g., switching therapies during follow-up, use of multiple products in combination or sequence, different dosing, and compliance).

详细描述

While the safety and efficacy of CognivAiD is established in clinical studies, this registry will assess the safe use and effectiveness of CognivAiD in the real-world setting. The design also takes into account the different scenarios of product use in the real world (e.g., switching therapies duObjectivesThe primary objective of this registry is to evaluate the use, safety, and effectiveness of CognivAiD This project is not a clinical trial wherein an active intervention intended to change human subject's outcome is implemented and takes decision-making away from the physician and patient. This registry uses an observational study design that does not specify or assign treatments or therapies. The registry is designed by keeping as closely as possible to real-world practice and as unobtrusive as possible to closely reflect usual practice and normal standards of care.

There are few inclusion and exclusion criteria to include a broad range of participants to make the results more generalizable. Participants are observed as they present for care and the data collected reflects existing tests, measurements, and treatments a healthcare provider customarily uses. Participation in the registry is entirely voluntary.

The primary objective of the registry is to evaluate the use, safety, and effectiveness of CognivAiD in a real-world setting. The primary data elements include the reporting of side effects and adverse events. Data collection and includes demographics, education, number of years, past medical history, CognivAiD information and, neurological status by the standard clinical practice and normal standard of care. Cognitive Assessment will be performed as per routine clinical visit. Collected data will be entered into the online study database.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 100 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female
  • Legal age as per country requirement
  • Already taking or having to receive a prescription for CognivAiD (decision must have been made before consideration to participate in the registry)
  • Agrees to be included in the registry, provides written consent inclusion criteria
  • Male or female
  • Legal age as per country requirement
  • Already taking or having to receive a prescription for CognivAiD (decision must have been made before consideration to participate in the registry)
  • Agrees to be included in the registry, provides written consent, and allows retrieval and analysis of data by local requirements.

排除标准

  • 未提供

结局指标

主要结局

Safety reporting

时间窗: baseline, one month, 3rd month, 6th month, 9th month and one year

The Registry will collect adverse events or side effects reported by the doctors .

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验